Mechanism of fibroblast-like synoviocyte apoptosis induced by recombinant human endostatin in rats with adjuvant arthritis.
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by pronounced synovial hyperplasia, in which there may be an imbalance between the growth and death of fibroblast-like synoviocytes (FLS). The present study was undertaken to examine the effect of recombinant human endostatin (rhEndostatin) on FLS apoptosis in experimental RA. Adjuvant arthritis (AA) was induced in male Sprague Dawley (SD) rats. Using cultured AA FLS obtained from these rats, the apoptosis process was measured by terminal deoxyribonucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) as well as Annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) labeling methods. In addition, the expression levels of the Fas, c-jun, NFkappaB, and caspase-3 gene products in synovial tissues were quantified by quantitative real-time polymerase chain reaction (qPCR) and/or Western blotting assays. Our data revealed that rhEndostatin induced apoptosis in AA FLS. The number and signal density of TUNEL-positive cells were significantly increased in rats treated with rhEndostatin (2.5 mg/kg). The percentage of Annexin V-FITC-positive cells was 6.67% after treatment with rhEndostatin at 25 microg/mL for 48 hr, compared with only 3.32% among untreated control cells. There were significant increases in Fas mRNA, c-jun mRNA, c-Jun protein, and caspase-3 (p20) protein in AA synovial tissues treated with rhEndostatin (2.5 mg/kg), whereas no significant difference in NFkappaB expression was detected between treated and untreated tissues. These findings indicate that rhEndostatin has a therapeutic effect on RA by inducing FLS apoptosis, which is strongly associated with increased expression of Fas, c-jun, and caspase-3, but not NFkappaB.
School of Pharmacy, Anhui Medical University, Hefei, China.
Xue-Ying
XY
Huang
Fei-Hu
FH
Chen
Jun
J
Li
Li-Juan
LJ
Xia
Yong-Jing
YJ
Liu
Xiao-Ming
XM
Zhang
Feng-Lai
FL
Yuan
D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D001169:Arthritis, Experimental / Q000473:pathology / Q000503:physiopathology*; D043169:Endostatins / Q000494:pharmacology*; D005347:Fibroblasts / Q000166:cytology* / Q000502:physiology*; D016650:Fluorescein-5-isothiocyanate; D006801:Humans; D008297:Male; D016328:NF-kappa B / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology; D013583:Synovial Membrane / Q000166:cytology* / Q000187:drug effects / Q000473:pathology / Q000502:physiology*
D043169:Endostatins; D016328:NF-kappa B; D011994:Recombinant Proteins; D016650:Fluorescein-5-isothiocyanate